QCA First Fund--FFIII Portfolio

QCA First Fund IV Portfolio Companies

Ischemia Care is commercializing a blood test for the accurate diagnosis of stroke and TIA (Transient Ischemic Attacks). The test, to be used primarily in emergency rooms, will give doctors important additional information to aid in appropriate treatment and to improve outcomes. The technology has been licensed from UC Davis, where it has been under development for many years.

The company has previously had support from QCA First Fund III, QCA members and others. QCA First Fund IV has now invested to allow the company to begin commercialization of the test.

Capstory has developed a web application initially targeted at the wedding industry to help every bride remember the moments before, during and after her wedding with full service from collecting photos to final editing and showcasing. Their proprietary technology allows guests at an event to capture images and video and send it via text to a secure site where the images can be accumulated, enhanced, and published.

Previous funding from CincyTech allowed them to develop the technology. Funding from QCA First Fund IV will allow them to launch the product and begin sales.

Cladwell is an online clothing service that helps millennial men buy clothes that look great on them for work or play. Their proprietary matching algorithm makes sure that each customer gets the best possible individual recommendations.

The Fund has joined with QCA members and others to support the initial commercial launch of the service.

Medacheck is a technology development company creating an integrated delivery platform for medication adherence, hospital discharge processing, and caretaker assistance. Its hardware and software will improve lives and save significant costs for the healthcare system.

QCA First Fund IV and QCA members are providing the necessary capital to complete beta testing and begin commercial sales.

Formerly called Bioformix, Sirrus advances manufacturing technology through chemistry relating to the synthesis, stabilization, activation and formulation of a unique and reactive class of monomers commonly known as methylene malonates. These monomers, their derivatives and resulting polymer platforms provide the foundation for enabling new assembly techniques and energy savings.

QCA FF IV joins Fund III and many other funders to enable the company to continue its product development and begin sales.

GenSyn offers breakthrough particle engineering for life science companies. They can make targeted-size active pharmaceutical ingredients in the nano- and micro-size range to meet the demands of the pharmaceutical industry.

The Fund joins Early Stage Partners as the primary funders of the company, which is has begun selling its capabilities on a project basis.

Neuros Medical, a Cleveland, Ohio based neurostimulation company, is focused on developing proprietary neurostimulation therapies for unmet needs to patients worldwide. The company’s patented platform technology will provide patients with elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post surgical pain, and chronic migraine.

The company was originally funded by QCA FF III and others. Fund IV has continued QCA's support.

CoupSmart has devised a simple, direct way to launch, manage, and measure marketing campaigns for brick and mortar businesses. From retail to consumer goods manufacturers to restaurants or service providers, they help businesses run powerful marketing campaigns via social media, mobile, email, and even in-store.

The Fund combined with FF III, OTAF, and a number of individual investors to support the company's growth.

Petbrosia is a disruptive innovation in pet health, which utilizes technology to deliver a breakthrough product and service to better meet consumer’s increasing desires to do the best for their pets. Customers input information about their pets and a unique blend of food is created and shipped directly to them.

North Coast Angel Fund and CincyTech are among the other investors in Petbrosia.

Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children’s Hospital Medical Center (CCHMC) for further development of products that address various needs for lung disorders.

CCHMC, CincyTech and others join the Fund with investments in the company.

Liquid is a website and mobile app which allows the easy collection, analysis and collaboration over data in real time. It answers an unmet need in the scientific community for more efficient and effective collection and use of data.

The Fund has joined with QCA members and Differential to support the creation of the company.

Fanping is helping to connect Chinese students with US universities and employers. Using the company's technology, Fanping can confirm the applicant's identity and English proficiency to insure that there is a good match.

The Fund has joined with QCA members to launch the company.

T-Pro provides consumer packaged goods clients with a cloud-based platform that integrates, automates, and optimizes trade promotions. Using its software, companies can determine which trade promotions are actually working.

OTAF and others are our investment partners in T-Pro.